Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury
- PMID: 10202927
- DOI: 10.1038/7391
Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury
Abstract
Pseudomonas aeruginosa is an opportunistic bacterial pathogen that can cause fatal acute lung infections in critically ill individuals. Damage to the lung epithelium is associated with the expression of toxins that are directly injected into eukaryotic cells through a type Ill-mediated secretion and translocation mechanism. Here we show that the P. aeruginosa homolog of the Yersinia V antigen, PcrV, is involved in the translocation of type III toxins. Vaccination against PcrV ensured the survival of challenged mice and decreased lung inflammation and injury. Antibodies to PcrV inhibited the translocation of type III toxins.
Comment in
-
For Pseudomonas aeruginosa, stealth is no longer enough.Nat Med. 1999 Apr;5(4):378-9. doi: 10.1038/7372. Nat Med. 1999. PMID: 10202921 No abstract available.
Similar articles
-
Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.Microbiol Immunol. 2009 Nov;53(11):587-94. doi: 10.1111/j.1348-0421.2009.00165.x. Microbiol Immunol. 2009. PMID: 19903258
-
Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.Burns. 2005 Mar;31(2):153-8. doi: 10.1016/j.burns.2004.09.002. Burns. 2005. PMID: 15683685
-
PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.Respir Physiol Neurobiol. 2014 Mar 1;193:21-8. doi: 10.1016/j.resp.2014.01.001. Epub 2014 Jan 10. Respir Physiol Neurobiol. 2014. PMID: 24418353
-
Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.Expert Rev Vaccines. 2005 Oct;4(5):645-56. doi: 10.1586/14760584.4.5.645. Expert Rev Vaccines. 2005. PMID: 16221066 Review.
-
V-antigen homologs in pathogenic gram-negative bacteria.Microbiol Immunol. 2014 May;58(5):267-85. doi: 10.1111/1348-0421.12147. Microbiol Immunol. 2014. PMID: 24641673 Review.
Cited by
-
Ventilator-associated pneumonia caused by Pseudomonas aeruginosa: cap your needles!Crit Care Med. 2012 Aug;40(8):2503-4. doi: 10.1097/CCM.0b013e318258e5bb. Crit Care Med. 2012. PMID: 22809923 Free PMC article. No abstract available.
-
The type III pseudomonal exotoxin U activates the c-Jun NH2-terminal kinase pathway and increases human epithelial interleukin-8 production.Infect Immun. 2006 Jul;74(7):4104-13. doi: 10.1128/IAI.02045-05. Infect Immun. 2006. PMID: 16790784 Free PMC article.
-
Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen).Infect Immun. 2003 Jul;71(7):3673-81. doi: 10.1128/IAI.71.7.3673-3681.2003. Infect Immun. 2003. PMID: 12819047 Free PMC article. Review. No abstract available.
-
Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils.Infect Immun. 2000 May;68(5):2916-24. doi: 10.1128/IAI.68.5.2916-2924.2000. Infect Immun. 2000. PMID: 10768989 Free PMC article.
-
Thinking Outside the Bug: Molecular Targets and Strategies to Overcome Antibiotic Resistance.Int J Mol Sci. 2019 Mar 13;20(6):1255. doi: 10.3390/ijms20061255. Int J Mol Sci. 2019. PMID: 30871132 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical